Effective prevention of blood clots in critically ill patients

ISRCTN ISRCTN03037804
DOI https://doi.org/10.1186/ISRCTN03037804
EudraCT/CTIS number 2005-002381-10
Secondary identifying numbers EudraCT: 2005-002381-10
Submission date
03/02/2010
Registration date
22/02/2010
Last edited
16/05/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Palle Toft
Scientific

Department of Anaesthesia and Intensive Care
Odense University Hospital
Sdr. Boulevard 29.
Odense
DK 5000
Denmark

Study information

Study designProspective randomised double-blinded controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleEnoxaparin - effective dosage for intensive care patients: a double-blinded, randomised clinical trial
Study objectivesInadequate dosage of enoxaparin may be a possible explanation for the high failure rate of thromboembolic prophylaxis in intensive care unit (ICU) patients. The administration of higher doses of enoxaparin may give better anti-factor Xa levels in ICU patients and may thereby confer a greater degree of protection against venous thromboembolism.
Ethics approval(s)Local medical ethics committee (Den Videnskabsetisk Komite for Vejle og Fyn) approved on the 3rd June 2005 (ref: VF-2004-0225)
Health condition(s) or problem(s) studiedVenous thromboembolism
InterventionPatients were randomised into four groups/arms to receive one of the following subcutaneous doses of enoxaparin (Clexane®): 40, 50, 60, or 70 mg for a period of 24 hours. Patients receiving 40 mg (the standard thromboprophylactic dose of enoxaparin) acted as the control group, while patients receiving 50, 60, and 70 mg were considered intervention groups. The total duration of treatment and follow-up was 24 hours.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Enoxaparin
Primary outcome measurePeak anti-factor Xa levels (peak = 4 hours post-enoxaparin administration). Levels of anti-factor Xa activity were determined using a validated chromogenic assay kit (COAMATIC Heparin, Chromogenix, Instrumentation Laboratory Company, Lexington, USA) with the substrate S-2732, and the apparatus (STA-R Evolution, Diagnostica Stago, Asnieres, France).
Secondary outcome measures1. Antithrombin (AT)
2. Prothrombin time (PT)
3. Activated partial thromboplastin time (aPTT)
4. Thrombin-antithrombin complexes (TAT), determined using an enzyme-immunoassay (Enzygnostâ TAT micro, Siemens, Marburg, Germany)
5. Fibrinogen
6. Platelets
7. D-dimer

Measured immediately before, and at 4, 12, and 24 hours after the administration of enoxaparin.
Overall study start date01/02/2006
Completion date31/03/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants80 patients
Key inclusion criteria1. Consecutive patients admitted to the ICU
2. Aged over 18 years, either sex
3. Minimum stay of greater than 24 hours
Key exclusion criteria1. Patients weighing less than 50 kg or greater than 90 kg
2. Bleeding diathesis
3. In need of an operation within the timeframe of the study
4. Pregnant
5. Requiring continuous veno-venous haemofiltration
Date of first enrolment01/02/2006
Date of final enrolment31/03/2009

Locations

Countries of recruitment

  • Denmark

Study participating centre

Department of Anaesthesia and Intensive Care
Odense
DK 5000
Denmark

Sponsor information

Odense University Hospital (Denmark)
Hospital/treatment centre

Department of Anaesthesia and Intensive Care
Sdr. Boulevard 29.
Odense
DK 5000
Denmark

Website http://www.ouh.dk/wm259883
ROR logo "ROR" https://ror.org/00ey0ed83

Funders

Funder type

Charity

Professor Sophus H Johansens Foundation (Denmark)

No information available

Danielsens Foundation (Denmark)

No information available

The Danish Society of Anaesthesiology and Intensive Medicines Research Initiative (Denmark)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 16/05/2019 No No

Editorial Notes

16/05/2019: Added clinicaltrialsregister.eu link to basic results (scientific).